An Open-Label, Multicenter, Phase 2 Study Assessing the Safety and Efficacy of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis
Latest Information Update: 15 Sep 2023
Price :
$35 *
At a glance
- Drugs Navtemadlin (Primary) ; TL 895 (Primary)
- Indications Essential thrombocythaemia; Myelofibrosis; Polycythaemia vera
- Focus Therapeutic Use
- Sponsors Kartos Therapeutics
- 12 Sep 2023 Planned number of patients changed from 52 to 104.
- 03 May 2023 This trial has been completed in Poland, according to European Clinical Trials Database record.
- 12 May 2021 New trial record